+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Myriad Genetics Inc (MYGN) - Financial and Strategic SWOT Analysis Review

Myriad Genetics Inc (MYGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, engaged in the discovery and commercialization of molecular diagnostic tests, and personalized medicine, and provides pharmaceutical and clinical services for major diseases. The company’s product portfolio includes molecular diagnostic testing products that analyze genes, genetic expressions, and corresponding proteins to assess a person’s risk for developing diseases later in life; products related to diagnosis of disease; and determine a patient’s likelihood of responding to a particular drug. Myriad markets its products through sales force in Europe and Canada and distributor agreements in countries in Canada, Middle East, Asia, and Australia. The company has operations in the US, Spain, France, Switzerland, the UK, Canada, Italy, Germany, Japan, Australia and the Netherlands. Myriad is headquartered in Salt Lake City, Utah, the US.

Myriad Genetics Inc Key Recent Developments

  • May 07, 2024: Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
  • Mar 21, 2024: Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
  • Feb 21, 2024: Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
  • Feb 15, 2024: Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Myriad Genetics Inc - Key Facts
  • Myriad Genetics Inc - Key Employees
  • Myriad Genetics Inc - Key Employee Biographies
  • Myriad Genetics Inc - Major Products and Services
  • Myriad Genetics Inc - History
  • Myriad Genetics Inc - Company Statement
  • Myriad Genetics Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Myriad Genetics Inc - Business Description
  • Product Category: Hereditary Cancer
  • Overview
  • Performance
  • Product Category: Pharmacogenomics
  • Overview
  • Performance
  • Product Category: Prenatal
  • Overview
  • Performance
  • Product Category: Tumor Profiling
  • Overview
  • Performance
  • Geographical Segment: Rest of world
  • Performance
  • Geographical Segment: United States
  • Performance
  • R&D Overview
  • Myriad Genetics Inc - Corporate Strategy
  • Myriad Genetics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Myriad Genetics Inc - Strengths
  • Myriad Genetics Inc - Weaknesses
  • Myriad Genetics Inc - Opportunities
  • Myriad Genetics Inc - Threats
  • Myriad Genetics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Myriad Genetics Inc, Medical Equipment, Deals By Year, 2018 to YTD 2024
  • Myriad Genetics Inc, Medical Equipment, Deals By Type, 2018 to YTD 2024
  • Myriad Genetics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 07, 2024: Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
  • Mar 21, 2024: Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
  • Feb 21, 2024: Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
  • Feb 15, 2024: Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
  • Jan 30, 2024: Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
  • Jan 09, 2024: Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
  • Jan 03, 2024: Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
  • Dec 20, 2023: Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
  • Nov 16, 2023: Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
  • Nov 01, 2023: Myriad Genetics Appoints Sam Raha as Chief Operating Officer
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Myriad Genetics Inc, Key Facts
  • Myriad Genetics Inc, Key Employees
  • Myriad Genetics Inc, Key Employee Biographies
  • Myriad Genetics Inc, Major Products and Services
  • Myriad Genetics Inc, History
  • Myriad Genetics Inc, Subsidiaries
  • Myriad Genetics Inc, Key Competitors
  • Myriad Genetics Inc, Ratios based on current share price
  • Myriad Genetics Inc, Annual Ratios
  • Myriad Genetics Inc, Interim Ratios
  • Myriad Genetics Inc, Medical Equipment, Deals By Year, 2018 to YTD 2024
  • Myriad Genetics Inc, Medical Equipment, Deals By Type, 2018 to YTD 2024
  • Myriad Genetics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Myriad Genetics Inc, Performance Chart (2019 - 2023)
  • Myriad Genetics Inc, Ratio Charts
  • Myriad Genetics Inc, Medical Equipment, Deals By Year, 2018 to YTD 2024
  • Myriad Genetics Inc, Medical Equipment, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Tempus Labs Inc
  • InVitae Corp
  • Ambry Genetics Corp
  • Quest Diagnostics Inc
  • Exact Sciences Corp
  • Hologic Inc
  • Laboratory Corporation of America
  • Natera Inc
  • Genomind Inc
  • DNA Diagnostics Center Inc
  • Caris Life Sciences Inc
  • Foundation Medicine Inc